|
1
|
Lee YJ, Kim JH, Kim SK, Ha SJ, Mok TS,
Mitsudomi T and Cho BC: Lung cancer in never smokers: Change of a
mindset in the molecular era. Lung Cancer. 72:9–15. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Oxnard GR, Binder A and Jänne PA: New
targetable oncogenes in non-small-cell lung cancer. J Clin Oncol.
31:1097–1104. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Koivunen JP, Mermel C, Zejnullahu K,
Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D and
Thomas R: EML4-ALK fusion gene and efficacy of an ALK kinase
inhibitor in lung cancer. Clin Cancer Res. 14:4275–4283. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kwak EL, Bang YJ, Camidge DR, Shaw AT,
Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, et al:
Anaplastic lymphoma kinase inhibition in non-small-cell lung
cancer. N Engl J Med. 363:1693–1703. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Seto T, Kiura K, Nishio M, Nakagawa K,
Maemondo M, Inoue A, Hida T, Yamamoto N, Yoshioka H, Harada M, et
al: CH5424802 (RO5424802) for patients with ALK-rearranged advanced
non-small-cell lung cancer (AF-001JP study): A single-arm,
open-label, phase 1–2 study. Lancet Oncol. 14:590–598. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shaw AT and Engelman JA: Ceritinib in
ALK-rearranged non-small-cell lung cancer. N Engl J Med.
370:2537–2539. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Katayama R, Shaw AT, Khan TM,
Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT,
Benes C, et al: Mechanisms of acquired crizotinib resistance in
ALK-rearranged lung cancers. Sci Transl Med. 4:120ra172012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yamaguchi N, Lucena-Araujo AR, Nakayama S,
de Figueiredo-Pontes LL, Gonzalez DA, Yasuda H, Kobayashi S, Costa
DB and Dual ALK: Dual ALK and EGFR inhibition targets a mechanism
of acquired resistance to the tyrosine kinase inhibitor crizotinib
in ALK rearranged lung cancer. Lung Cancer. 83:37–43. 2014.
View Article : Google Scholar :
|
|
10
|
Niederst MJ and Engelman JA: Bypass
mechanisms of resistance to receptor tyrosine kinase inhibition in
lung cancer. Sci Signal. 6:re62013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Crystal AS, Shaw AT, Sequist LV, Friboulet
L, Niederst MJ, Lockerman EL, Frias RL, Gainor JF, Amzallag A,
Greninger P, et al: Patient-derived models of acquired resistance
can identify effective drug combinations for cancer. Science.
346:1480–1486. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
An R, Wang Y, Voeller D, Gower A, Kim IK,
Zhang YW and Giaccone G: CRKL mediates EML4-ALK signaling and is a
potential therapeutic target for ALK-rearranged lung
adenocarcinoma. Oncotarget. 7:29199–29210. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sang J, Acquaviva J, Friedland JC, Smith
DL, Sequeira M, Zhang C, Jiang Q, Xue L, Lovly CM, Jimenez JP, et
al: Targeted inhibition of the molecular chaperone Hsp90 overcomes
ALK inhibitor resistance in non-small cell lung cancer. Cancer
Discov. 3:430–443. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Katayama R, Khan TM, Benes C, Lifshits E,
Ebi H, Rivera VM, Shakespeare WC, Iafrate AJ, Engelman JA and Shaw
AT: Therapeutic strategies to overcome crizotinib resistance in
non-small cell lung cancers harboring the fusion oncogene EML4-ALK.
Proc Natl Acad Sci USA. 108:7535–7540. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sequist LV, Gettinger S, Senzer NN,
Martins RG, Jänne PA, Lilenbaum R, Gray JE, Iafrate AJ, Katayama R,
Hafeez N, et al: Activity of IPI-504, a novel heat-shock protein 90
inhibitor, in patients with molecularly defined non-small-cell lung
cancer. J Clin Oncol. 28:4953–4960. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tonack S, Jenkinson C, Cox T, Elliott V,
Jenkins RE, Kitteringham NR, Greenhalf W, Shaw V, Michalski CW,
Friess H, et al: iTRAQ reveals candidate pancreatic cancer serum
biomarkers: Influence of obstructive jaundice on their performance.
Br J Cancer. 108:1846–1853. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen Z, Sasaki T, Tan X, Carretero J,
Shimamura T, Li D, Xu C, Wang Y, Adelmant GO, Capelletti M, et al:
Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung
adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res.
70:9827–9836. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ross PL, Huang YN, Marchese JN, Williamson
B, Parker K, Hattan S, Khainovski N, Pillai S, Dey S, Daniels S, et
al: Multiplexed protein quantitation in Saccharomyces cerevisiae
using amine-reactive isobaric tagging reagents. Mol Cell
Proteomics. 3:1154–1169. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang S, Huang WC, Li P, Guo H, Poh SB,
Brady SW, Xiong Y, Tseng LM, Li SH, Ding Z, et al: Combating
trastuzumab resistance by targeting SRC, a common node downstream
of multiple resistance pathways. Nat Med. 17:461–469. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kang CW, Jang KW, Sohn J, Kim SM, Pyo KH,
Kim H, Yun MR, Kang HN, Kim HR, Lim SM, et al: Antitumor activity
and acquired resistance mechanism of dovitinib (TKI258) in
RET-rearranged lung adenocarcinoma. Mol Cancer Ther. 14:2238–2248.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Subbannayya Y, Syed N, Barbhuiya MA, Raja
R, Marimuthu A, Sahasrabuddhe N, Pinto SM, Manda SS, Renuse S,
Manju HC, et al: Calcium calmodulin dependent kinase kinase 2 - a
novel therapeutic target for gastric adenocarcinoma. Cancer Biol
Ther. 16:336–345. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu J, Li L, Yu G, Ying W, Gao Q, Zhang W,
Li X, Ding C, Jiang Y, Wei D, et al: The neddylation-cullin 2-RBX1
E3 ligase axis targets tumor suppressor RhoB for degradation in
liver cancer. Mol Cell Proteomics. 14:499–509. 2015. View Article : Google Scholar :
|
|
23
|
Schlaepfer DD and Hunter T: Evidence for
in vivo phosphorylation of the Grb2 SH2-domain binding site on
focal adhesion kinase by Src-family protein-tyrosine kinases. Mol
Cell Biol. 16:5623–5633. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schlaepfer DD and Mitra SK: Multiple
connections link FAK to cell motility and invasion. Curr Opin Genet
Dev. 14:92–101. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bromann PA, Korkaya H and Courtneidge SA:
The interplay between Src family kinases and receptor tyrosine
kinases. Oncogene. 23:7957–7968. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Parsons JT and Parsons SJ: Src family
protein tyrosine kinases: Cooperating with growth factor and
adhesion signaling pathways. Curr Opin Cell Biol. 9:187–192. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Biscardi JS, Maa MC, Tice DA, Cox ME, Leu
TH and Parsons SJ: c-Src-mediated phosphorylation of the epidermal
growth factor receptor on Tyr845 and Tyr1101 is associated with
modulation of receptor function. J Biol Chem. 274:8335–8343. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Belsches-Jablonski AP, Biscardi JS, Peavy
DR, Tice DA, Romney DA and Parsons SJ: Src family kinases and HER2
interactions in human breast cancer cell growth and survival.
Oncogene. 20:1465–1475. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Isozaki H, Ichihara E, Takigawa N, Ohashi
K, Ochi N, Yasugi M, Ninomiya T, Yamane H, Hotta K, Sakai K, et al:
Non-small cell lung cancer cells acquire resistance to the ALK
inhibitor alectinib by activating alternative receptor tyrosine
kinases. Cancer Res. 76:1506–1516. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tani T, Yasuda H, Hamamoto J, Kuroda A,
Arai D, Ishioka K, Ohgino K, Miyawaki M, Kawada I, Naoki K, et al:
Activation of EGFR bypass signaling by TGFα overexpression induces
acquired resistance to alectinib in ALK-translocated lung cancer
cells. Mol Cancer Ther. 15:162–171. 2016. View Article : Google Scholar
|
